Alzheimer’s disease is a progressive brain disease that slowly destroys memory, thinking ability, and eventually the capacity to carry out everyday tasks. It is the most common cause of dementia, accounting for the majority of cases among the estimated 7.1 million Americans currently living with dementia symptoms. That number is projected to nearly double to 13.9 million by 2060. Globally, more than 50 million people live with some form of dementia.
Alzheimer’s vs. Dementia
These two terms are often used interchangeably, but they don’t mean the same thing. Dementia is an umbrella term describing a wide range of symptoms, including memory loss, confusion, and difficulty with reasoning. It is not a specific disease. Alzheimer’s is a specific brain disease and the most common type of dementia, though not the only one. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. When someone is diagnosed with dementia, identifying the underlying cause matters because the progression and management differ.
What Happens Inside the Brain
Alzheimer’s involves two key proteins that build up abnormally in the brain: beta-amyloid and tau. Beta-amyloid is a fragment left over from the normal breakdown of a larger protein. In a healthy brain, these fragments are cleared away. In Alzheimer’s, a particularly toxic form of beta-amyloid (called beta-amyloid 42) clumps together into sticky plaques that accumulate between nerve cells and disrupt their function.
The second protein, tau, normally helps maintain the internal structure of nerve cells. Think of it as scaffolding that keeps a cell’s transport system running smoothly, allowing nutrients and signals to move where they need to go. In Alzheimer’s, tau undergoes abnormal chemical changes, detaches from the cell’s internal structure, and clumps into tangles inside neurons. These tangles block the cell’s transport system, impairing communication between nerve cells.
Current evidence suggests these two problems interact. Beta-amyloid plaques appear to accumulate first, and once they reach a tipping point, tau spreads rapidly through brain regions involved in memory and cognition. The disease process actually begins years before any symptoms appear, silently altering brain chemistry during what doctors call the preclinical stage.
Early Warning Signs
Normal aging brings some forgetfulness. You might occasionally lose your car keys, struggle to find a word that comes to you later, or blank on an acquaintance’s name. These are not cause for alarm. Alzheimer’s looks different. The signs that distinguish it from typical aging include:
- Getting lost in familiar places, like your own neighborhood
- Using unusual words for everyday objects because you can’t recall the right term
- Forgetting the names of close family members or friends, not just acquaintances
- Losing old, well-established memories, not just recent ones
- Struggling to complete routine tasks you’ve done independently for years
The key difference is impact. Forgetting where you parked at the grocery store is normal. Forgetting how you got to the grocery store is not.
How the Disease Progresses
Alzheimer’s exists on a continuum, and the pace varies from person to person. But most people move through recognizable stages.
Preclinical Stage
Brain changes are already underway, but neither the person nor anyone around them notices symptoms. This stage can last years or even decades. It is only detectable through biomarker testing.
Mild Cognitive Impairment
Memory lapses become noticeable but don’t yet interfere significantly with daily life. A person might forget appointments, have trouble estimating how long a task will take, or struggle to plan the steps needed to complete something. Decision-making may start to feel harder than it used to.
Mild Dementia
This is when the disease starts to meaningfully disrupt daily routines. People ask the same questions repeatedly, have trouble balancing a checkbook or planning an event, and may make poor financial decisions. Personality shifts can appear: a previously social person might become withdrawn, or someone who was even-tempered might become irritable. Finding the right words becomes harder, and getting lost in once-familiar places becomes more common.
Moderate Dementia
Confusion deepens considerably. People lose track of where they are, what day it is, or what season it is. They may confuse family members with one another or mistake strangers for people they know. Personal history starts to fade, including details like their own phone number or where they went to school. Assistance with bathing, dressing, and using the bathroom becomes necessary. Behavioral changes intensify during this stage. Some people develop unfounded suspicions, accusing loved ones of stealing or infidelity. Others may see or hear things that aren’t there. Restlessness and agitation, particularly in the late afternoon and evening, are common.
Risk Factors You Can and Can’t Control
Age is the biggest risk factor, and you can’t change that. Genetics also play a role. A gene variant called APOE e4 is the most significant genetic risk factor. Carrying one copy of this variant doubles or triples the risk of developing Alzheimer’s. Carrying two copies increases risk 8 to 12 times. Still, having the gene variant doesn’t guarantee disease, and many people with Alzheimer’s don’t carry it.
What’s increasingly clear is how much lifestyle and health conditions matter. A landmark report from the Lancet Commission identified 14 modifiable risk factors across a person’s lifespan that together could account for roughly 45% of dementia cases worldwide. In early life, the key factor is education. In midlife, the risks include hearing loss, traumatic brain injury, high blood pressure, excessive alcohol use, and obesity. In later life, smoking, depression, social isolation, physical inactivity, diabetes, air pollution, vision loss, and high cholesterol all contribute. None of these guarantees or prevents Alzheimer’s on its own, but collectively they represent a substantial portion of risk that is within reach to address.
How Alzheimer’s Is Diagnosed
For decades, an Alzheimer’s diagnosis relied heavily on clinical evaluation: memory tests, cognitive assessments, and ruling out other causes. A definitive diagnosis was only possible after death, through examination of brain tissue. That has changed.
Revised diagnostic criteria now define Alzheimer’s as a biological process, not just a set of symptoms. The disease is identified through biomarkers, measurable signs of the amyloid and tau changes happening in the brain. These can be detected through brain imaging (PET scans) or fluid tests (spinal fluid or blood). One of the most significant recent advances is a blood test measuring a specific form of tau protein (phosphorylated tau 217), which can identify Alzheimer’s-related brain changes with high accuracy, over 95% sensitivity in clinical studies. This makes biological diagnosis far more accessible than it was when PET scans and spinal taps were the only options.
This shift matters because brain changes begin long before symptoms appear. Detecting the disease early opens a window for intervention, particularly as new treatments become available that target the disease’s biology rather than just managing symptoms.
Current Treatments
There is no cure for Alzheimer’s, but the treatment landscape has shifted significantly. For years, the only medications available managed symptoms, temporarily improving memory and thinking by boosting chemical signaling between brain cells. These drugs don’t slow the disease itself.
A newer class of treatments targets amyloid plaques directly. The FDA has approved drugs including donanemab (sold as Kisunla), which works by helping the body clear amyloid buildup from the brain. These treatments are specifically for people in the early stages of the disease, those with mild cognitive impairment or mild dementia who have confirmed amyloid buildup in the brain. Genetic testing for the APOE e4 variant is performed before starting treatment because carriers face a higher risk of a side effect involving brain swelling or small bleeds.
These newer therapies slow cognitive decline rather than stop it entirely, and they are not appropriate for everyone. But they represent the first treatments that address the underlying disease process rather than its symptoms alone.